Molecular Oncogenesis of Lung Cancer

  • Arwen A. Stelter
  • Jingwu Xie
Part of the Molecular Pathology Library book series (MPLB, volume 1)


In 2005, cancer surpassed heart disease as the leading cause for death in Americans under the age of 80 years. Among all types of human cancer, lung cancer is the leading cause of cancer-related death, claiming more than 150,000 lives every year in the United States alone (which exceeds the combined mortality from breast, prostate, colorectal, and pancreatic cancers). Patients with advanced stages of lung cancer, representing 75% of all new cases, have a median survival time of only 10 months.1 In contrast to the significant medical burden associated with lung cancer, research on lung cancer is underfunded. According to National Institutes of Health data (, the U.S. government spent approximately $1,200 per lung cancer death in 2002 on research compared with $11,425 for breast cancer, $8,190 for prostate cancer, and $3,350 for colorectal cancer. Approximately $31,000 was spent on research per HIV/AIDS death in 2002. Understanding the molecular basis of lung cancer progression and tumor metastasis is an essential step to reducing the mortality from lung cancer.


Lung Cancer Epidermal Growth Factor Receptor Small Cell Lung Cancer Human Lung Cancer Guanosine Triphosphate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Medley LT, Cullen MT. Best supportive care versus palliative chemotherapy in nonsmall-cell lung cancer. Curr Opin Oncol 2002;14(4):384–388.CrossRefPubMedGoogle Scholar
  2. 2.
    American Cancer Society. Cancer Facts and Figures 2006. Atlanta: American Cancer Society; 2006.Google Scholar
  3. 3.
    Tuveson DA, Jacks T. Modeling human lung cancer in mice: similarities and shortcomings. Oncogene 1999;18:5318–5324.CrossRefPubMedGoogle Scholar
  4. 4.
    Xie J. Identifying biomarkers of lung cancer in the postgenomic era. Curr Pharmacogenomics 2005;3(4):319–331.CrossRefGoogle Scholar
  5. 5.
    Sekido Y, Fong KM, Minna JD. Molecular genetics of lung cancer. Annu Rev Med 2003;54:73–87.CrossRefPubMedGoogle Scholar
  6. 6.
    Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710–1717.CrossRefPubMedGoogle Scholar
  7. 7.
    Toloza EM, Roth JA, Swisher SG. Molecular events in bronchogenic carcinoma and their implications for therapy. Semin Surg Oncol 2000;18:91–99.CrossRefPubMedGoogle Scholar
  8. 8.
    Hilbe W, Dirnhofer S, Greil R, et al. Biomarkers in non-small cell lung cancer prevention. Eur J Cancer Prev 2004;13:425–436.CrossRefPubMedGoogle Scholar
  9. 9.
    Girard L, Zochbauer-Muller S, Virmani AK, et al. Genomewide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res 2000;60:4894–4906.PubMedGoogle Scholar
  10. 10.
    Kranenburg O. The KRAS oncogene: past, present, and future. Biochim Biophys Acta 2005;1756(2):81–82.PubMedGoogle Scholar
  11. 11.
    Mascaux C, Iannino N, Martin B, et al. The role of RAS oncogene in survival of patients with lung cancer: a systemic review of the literature with meta-analysis. Br J Cancer 2005;92:131–139.CrossRefPubMedGoogle Scholar
  12. 12.
    Johnson L, Mercer K, Greenbaum D, et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001;410:1111–1116.CrossRefPubMedGoogle Scholar
  13. 13.
    Janne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 2005;23(14):3227–3234.CrossRefPubMedGoogle Scholar
  14. 14.
    Martin P, Kelly CM, Carney D. Epidermal growth factor receptor-targeted agents for lung cancer. Cancer Control 2006;13(2):129–140.PubMedGoogle Scholar
  15. 15.
    Shigematsu H, Gazdar AF. Somatic mutation of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006;118(2):257–262.CrossRefPubMedGoogle Scholar
  16. 16.
    Spicer J, Harper P. Targeted therapies for non-small cell lung cancer. Int J Clin Pract 2005;59(9):1055–1062.CrossRefPubMedGoogle Scholar
  17. 17.
    Miettinen M, Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol 2005;13:205–220.CrossRefPubMedGoogle Scholar
  18. 18.
    Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2005;366:1385–1396.CrossRefPubMedGoogle Scholar
  19. 19.
    Patel O, Shulkes A, Baldwin GS. Gastrin-releasing peptide and cancer. Biochim Biophys Acta 2006; [Epub ahead of print].Google Scholar
  20. 20.
    Watkins DN, Berman DM, Burkholder SG, et al. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 2003;422(6929):313–317.CrossRefPubMedGoogle Scholar
  21. 21.
    Chi S, Huang S, Li C, et al. Activation of the hedgehog pathway in a subset of lung cancers. Cancer Lett 2006; [Epub ahead of print].Google Scholar
  22. 22.
    He N, Li C, Zhang X, et al. Regulation of lung cancer cell growth and invasiveness by beta-TRCP. Mol Carcinog 2005;42(1):18–28.CrossRefPubMedGoogle Scholar
  23. 23.
    Haque AK, Au W, Cajas-Salazar N, et al. Association of patient smoking history, cyp2E1 polymorphism and p53 expression with patient survival in non-small cell lung cancer. Appl Immunohistochem Mol Morphol 2004;12(4):315–322.PubMedGoogle Scholar
  24. 24.
    Prives C, Hall PA. The p53 pathway. J Pathol 1999;187:112–126.CrossRefPubMedGoogle Scholar
  25. 25.
    Pietsch EC, Humbey O, Murphy ME. Polymorphisms in the p53 pathway. Oncogene 2006;25:1602–1611.CrossRefPubMedGoogle Scholar
  26. 26.
    Liu G, Chen X. Regulation of p53 transcriptional activity. J Cell Biochem 2006;97:448–458.CrossRefPubMedGoogle Scholar
  27. 27.
    Robles AI, Linke SP, Harris CC. The p53 network in lung carcinogenesis. Oncogene 2002;21:6898–6907.CrossRefPubMedGoogle Scholar
  28. 28.
    Rodin SN, Rodin AS. Origins and selection of p53 mutations in lung carcinogenesis. Semin Cancer Biol 2005;15:103–112.CrossRefPubMedGoogle Scholar
  29. 29.
    Viktorsson K, De Petris L, Lewensohn R. The role of p53 in treatment responses of lung cancer. Biochem Biophys Res Commun 2005;331:868–880.CrossRefPubMedGoogle Scholar
  30. 30.
    Olivier M, Eeles R, Hollstein M, et al. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002;19:607–614.CrossRefPubMedGoogle Scholar
  31. 31.
    Yu D, Berlin JA, Penning TM, et al. Reactive oxygen species generated by PAH o-quinones cause change-in-function mutations in p53. Chem Res Toxicol 2002;15:832–842.CrossRefPubMedGoogle Scholar
  32. 32.
    Wani MA, Zhu Q, El-Mahdy M, et al. Enhanced sensitivity to anti-benzo(a)pyrene-diol-epoxide DNA damage correlates with decreased global genomic repair attributable to abrogated p53 function in human cells. Cancer Res 2000;60:2273–2280.PubMedGoogle Scholar
  33. 33.
    Eymin B, Gazzeri S, Brambilla C, et al. Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors. Oncogene 2002;21:2750–2761.CrossRefPubMedGoogle Scholar
  34. 34.
    Nicholson SA, Okby NT, Khan MA, et al. Alterations in p14(ARF), p53 and p73 genes involved in the e2f-1-mediated apoptotic pathways in non-small cell lung carcinoma. Cancer Res 2001;61:5636–5643.PubMedGoogle Scholar
  35. 35.
    Dimova DK, Dyson NJ. The E2F transcriptional network: old acquaintances with new faces. Oncogene 2005;24:2810–2826.CrossRefPubMedGoogle Scholar
  36. 36.
    Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001;2:731–737.CrossRefPubMedGoogle Scholar
  37. 37.
    Rocco JW, Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res 2001;264:42–55.CrossRefPubMedGoogle Scholar
  38. 38.
    Yokota J, Kohno T. Molecular footprints of human lung cancer progression. Cancer Sci 2004;95(3):197–204.CrossRefPubMedGoogle Scholar
  39. 39.
    Brambilla E, Moro D, Gazzeri S, et al. Alterations of expression of Rb, p16(INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance. J Pathol 1999;188:351–360.CrossRefPubMedGoogle Scholar
  40. 40.
    Zou CP, Youssef EM, Zou CC, et al. Differential effects of chromosome 3p deletion on the expression of the putative tumor suppressor RARbeta and on retinoid resistance in human squamous carcinoma cells. Oncogene 2001;20:6820–6827.CrossRefPubMedGoogle Scholar
  41. 41.
    Minna JD, Fong K, Zochbauer-Muller S, et al. Molecular pathogenesis of lung cancer and potential translational applications. Cancer J 2002;8(Supp1):S41–S54.PubMedGoogle Scholar
  42. 42.
    Ito I, Ji L, Tanaka F, et al. Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo. Cancer Gene Ther 2004;11:733–739.CrossRefPubMedGoogle Scholar
  43. 43.
    Xian J, Clark KJ, Fordham R, et al. Inadequate lung development and bronchial hyperplasia in mice with a targeted deletion in the Dutt1/Robo1 gene. Proc Natl Acad Sci USA 2001;98(26):15062–15066.CrossRefPubMedGoogle Scholar
  44. 44.
    Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell 2003;113:673–676.CrossRefPubMedGoogle Scholar
  45. 45.
    Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004;64:3753–3756.CrossRefPubMedGoogle Scholar
  46. 46.
    Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell 2005;120:635–647.CrossRefPubMedGoogle Scholar
  47. 47.
    Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9(3):189–198.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • Arwen A. Stelter
    • 1
  • Jingwu Xie
    • 1
  1. 1.Department of Pharmacology and ToxicologyUniversity of Texas Medical BranchGalvestonUSA

Personalised recommendations